vimarsana.com

இந்தியன் மருந்து உற்பத்தியாளர்கள் சங்கம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Drugmakers cry monopoly as Modi govt picks 1 firm each to make over 20 key raw materials

Drugmakers cry ‘monopoly’ as Modi govt picks 1 firm each to make over 20 key raw materials Himani Chandna © Provided by The Print New Delhi: India’s weapon to fight its dependence on Chinese medicine imports the Production-Linked Incentive scheme may end up creating a monopoly of just a few drugmakers, and the pharma lobby has expressed its concern about this to the Narendra Modi government. The PLI scheme launched by the government in July provides monetary incentives to increase the production of 41 critical raw materials, including active pharmaceutical ingredients (APIs), intermediates and key starting materials, distributed in four categories, that are required for manufacturing final formulations (medicines) in India.

Remdesivir output up, but supply bottlenecks remain - The Hindu BusinessLine

Remdesivir output up, but supply bottlenecks remain × The production of most sought after anti-viral drug, Remdesivir, has increased significantly but its availability continues to be a challenge in some States and private hospitals. The production capacity of the remdesivir injection by seven domestic manufacturers has increased from 38 lakh vials per month to nearly 119 lakh vials, the Ministry of Chemicals and Fertilisers said on Monday. Developed by US-based Gilead Sciences Inc, Remdesivir is being used to treat Covid-19 patients with oxygen saturation below 95 per cent and those with moderate to severe symptoms. Hyderabad-based Hetero Drugs is a major manufacturer of Remdisivir followed by Cipla, Zydus Cadila, Mylan Labs, Dr Reddy’s Labs, Syngene and Jubilant Ingrevia.

India s covid collapse, part 6: The boom in black market for live-saving drugs

UPDATED: May 12, 2021 09:24 IST LIFELINE: A Chennai resident with Remdesivir purchased from a government facility (Arun Sankar/Getty Images) When a harried Naresh Indulkar, a resident of Mumbai’s Thane, went searching for three vials of Remdesivir for a relative in critical condition in hospital, it took nearly six hours to find a pharmacy with stock. “Rs 22,000 a vial,” whispered the man behind the counter, though the marked retail price was only Rs 1,800. Distraught, Indulkar returned to his apartment. A glimmer of hope appeared in the form of a reply from his neighbour to an appeal he had posted on his residential society’s WhatsApp group. On calling him, the neighbour came up two floors and offered Indulkar three spare vials of Remdesivir he had. “He had bought eight vials at a premium to treat his father,” recalls Indulkar. “Five sufficed, and as thanksgiving, he offered me the rest at the marked price, unmindful of his financial loss.”

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.